Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.

Important note: Information in this article was accurate in 2000. The state of the art may have changed since the publication date.

Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority patient population.

Ann Pharmacother. 2000 May;34(5):580-4. Unique Identifier : AIDSLINE MED/20308923
Dever LL; Oruwari PA; Figueroa WE; O'Donovan CA; Eng RH; Infectious Diseases Clinic, Veterans Affairs New Jersey Health; Care System, East Orange 07018, USA.; dever.lisa@east-orange.va.gov

Abstract: BACKGROUND: Hyperglycemia and new-onset diabetes mellitus have been reported to occur in HIV-infected patients treated with protease inhibitors. OBJECTIVE: To determine the effect of protease inhibitor therapy on serum glucose in a predominantly minority patient population. DESIGN: Retrospective record review. SETTING: Clinical HIV program of an urban Veterans Affairs medical center. PATIENTS: All HIV-infected patients receiving a protease inhibitor over a one-year period from September 1996 through August 1997. RESULTS: One hundred seventeen patients not previously known to be diabetic received protease inhibitors; seven (6%) developed symptomatic diabetes mellitus. Eight other patients had one or more serum glucose values >150 mg/dL. Mean random glucose values for patients who did not develop diabetes were higher during therapy than prior to initiation of protease inhibitors. CONCLUSIONS: Urban minority HIV-infected patients receiving combination antiretroviral therapy including a protease inhibitor may be at increased risk for the development of hyperglycemia and diabetes mellitus. Risk factors for diabetes mellitus should be identified and blood glucose monitored in all patients receiving protease inhibitors.

Keywords: JOURNAL ARTICLE Adult Blood Glucose/ANALYSIS Diabetes Mellitus, Non-Insulin-Dependent/*CHEMICALLY INDUCED Female Human Hyperglycemia/*CHEMICALLY INDUCED HIV Infections/*DRUG THERAPY HIV Protease Inhibitors/*ADVERSE EFFECTS/THERAPEUTIC USE Indinavir/ADVERSE EFFECTS/THERAPEUTIC USE Male Middle Age Minority Groups/STATISTICS & NUMER DATA Retrospective Studies Risk Factors Ritonavir/ADVERSE EFFECTS/THERAPEUTIC USE Saquinavir/ADVERSE EFFECTS/THERAPEUTIC USE Urban Population/STATISTICS & NUMER DATA

001230
A00C0932

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .